These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

442 related items for PubMed ID: 19146377

  • 41. A combined approach to drug metabolism and toxicity assessment.
    Ekins S, Andreyev S, Ryabov A, Kirillov E, Rakhmatulin EA, Sorokina S, Bugrim A, Nikolskaya T.
    Drug Metab Dispos; 2006 Mar; 34(3):495-503. PubMed ID: 16381662
    [Abstract] [Full Text] [Related]

  • 42. A rapid method for quantitatively estimating metabolites in human plasma in the absence of synthetic standards using a combination of liquid chromatography/mass spectrometry and radiometric detection.
    Yu C, Chen CL, Gorycki FL, Neiss TG.
    Rapid Commun Mass Spectrom; 2007 Mar; 21(4):497-502. PubMed ID: 17221928
    [Abstract] [Full Text] [Related]

  • 43. In vitro - in vivo correlation: from theory to applications.
    Emami J.
    J Pharm Pharm Sci; 2006 Mar; 9(2):169-89. PubMed ID: 16959187
    [Abstract] [Full Text] [Related]

  • 44. A holistic strategy for characterizing the safety of metabolites through drug discovery and development.
    Walker D, Brady J, Dalvie D, Davis J, Dowty M, Duncan JN, Nedderman A, Obach RS, Wright P.
    Chem Res Toxicol; 2009 Oct; 22(10):1653-62. PubMed ID: 19715349
    [Abstract] [Full Text] [Related]

  • 45. Application of chimeric mice with humanized liver for study of human-specific drug metabolism.
    Bateman TJ, Reddy VG, Kakuni M, Morikawa Y, Kumar S.
    Drug Metab Dispos; 2014 Jun; 42(6):1055-65. PubMed ID: 24700822
    [Abstract] [Full Text] [Related]

  • 46. Metabolomics in pharmaceutical research and development: metabolites, mechanisms and pathways.
    Xu EY, Schaefer WH, Xu Q.
    Curr Opin Drug Discov Devel; 2009 Jan; 12(1):40-52. PubMed ID: 19152212
    [Abstract] [Full Text] [Related]

  • 47. In vivo and in vitro metabolism of lefucoxib in rats.
    Bi X, Meng Z, Chen H, Zhu X, Dou G.
    J Pharm Biomed Anal; 2008 Sep 10; 48(1):134-9. PubMed ID: 18538525
    [Abstract] [Full Text] [Related]

  • 48. Prediction of human pharmacokinetics--improving microsome-based predictions of hepatic metabolic clearance.
    Fagerholm U.
    J Pharm Pharmacol; 2007 Oct 10; 59(10):1427-31. PubMed ID: 17910819
    [Abstract] [Full Text] [Related]

  • 49. Application of a Micropatterned Cocultured Hepatocyte System To Predict Preclinical and Human-Specific Drug Metabolism.
    Ballard TE, Wang S, Cox LM, Moen MA, Krzyzewski S, Ukairo O, Obach RS.
    Drug Metab Dispos; 2016 Feb 10; 44(2):172-9. PubMed ID: 26608083
    [Abstract] [Full Text] [Related]

  • 50. In vitro to in vivo extrapolation for trichloroethylene metabolism in humans.
    Lipscomb JC, Fisher JW, Confer PD, Byczkowski JZ.
    Toxicol Appl Pharmacol; 1998 Oct 10; 152(2):376-87. PubMed ID: 9853006
    [Abstract] [Full Text] [Related]

  • 51. Software-aided structural elucidation in drug discovery.
    Ahlqvist M, Leandersson C, Hayes MA, Zamora I, Thompson RA.
    Rapid Commun Mass Spectrom; 2015 Nov 15; 29(21):2083-9. PubMed ID: 26443410
    [Abstract] [Full Text] [Related]

  • 52. Database Extraction of Metabolite Information of Drug Candidates: Analysis of 27 AstraZeneca Compounds with Human Absorption, Distribution, Metabolism, and Excretion Data.
    Iegre J, Hayes MA, Thompson RA, Weidolf L, Isin EM.
    Drug Metab Dispos; 2016 May 15; 44(5):732-40. PubMed ID: 26868617
    [Abstract] [Full Text] [Related]

  • 53. Evaluation of drug metabolism, drug-drug interactions, and in vitro hepatotoxicity with cryopreserved human hepatocytes.
    Li AP.
    Methods Mol Biol; 2010 May 15; 640():281-94. PubMed ID: 20645058
    [Abstract] [Full Text] [Related]

  • 54. Recent advances in physicochemical and ADMET profiling in drug discovery.
    Wang J, Skolnik S.
    Chem Biodivers; 2009 Nov 15; 6(11):1887-99. PubMed ID: 19937823
    [Abstract] [Full Text] [Related]

  • 55. Current and future trends in the application of HPLC-MS to metabolite-identification studies.
    Castro-Perez JM.
    Drug Discov Today; 2007 Mar 15; 12(5-6):249-56. PubMed ID: 17331890
    [Abstract] [Full Text] [Related]

  • 56. A strategy for the risk assessment of human genotoxic metabolites.
    Dobo KL, Obach RS, Luffer-Atlas D, Bercu JP.
    Chem Res Toxicol; 2009 Feb 15; 22(2):348-56. PubMed ID: 19170655
    [Abstract] [Full Text] [Related]

  • 57. Hepatocellular binding of drugs: correction for unbound fraction in hepatocyte incubations using microsomal binding or drug lipophilicity data.
    Kilford PJ, Gertz M, Houston JB, Galetin A.
    Drug Metab Dispos; 2008 Jul 15; 36(7):1194-7. PubMed ID: 18411401
    [Abstract] [Full Text] [Related]

  • 58. Integrated strategies for assessment of metabolite exposure in humans during drug development: analytical challenges and clinical development considerations.
    Zhu M, Zhang D, Zhang H, Shyu WC.
    Biopharm Drug Dispos; 2009 May 15; 30(4):163-84. PubMed ID: 19544287
    [Abstract] [Full Text] [Related]

  • 59. Induction of drug metabolizing enzymes: a survey of in vitro methodologies and interpretations used in the pharmaceutical industry--do they comply with FDA recommendations?
    Hewitt NJ, de Kanter R, LeCluyse E.
    Chem Biol Interact; 2007 May 20; 168(1):51-65. PubMed ID: 17239835
    [Abstract] [Full Text] [Related]

  • 60. Beyond profiling: using ADMET models to guide decisions.
    Segall M, Champness E, Obrezanova O, Leeding C.
    Chem Biodivers; 2009 Nov 20; 6(11):2144-51. PubMed ID: 19937845
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.